Associated tags: Disorder, Obesity, Adenosine, Medication, Opioid use disorder, Pain, Gambling, Addiction, Drinking, Pharmaceutical industry, Patient, AUD
Locations: EUROPE, AUSTRIA, NEW YORK CITY, FAA, CHARLOTTESVILLE, VA, US, CLAIBORNE, AST, AUD, AE, UNITED STATES
Life,
Personalized medicine,
Biomedical Research,
AUD,
Patient,
Medicine,
European Society for Medical Oncology,
Congress,
Safety,
Pharmaceutical industry,
Alcoholism Session 11: Treatment of alcohol use disorder: safety and efficacy of precision medicine in selected patients
Key Points:
- Session 11: Treatment of alcohol use disorder: safety and efficacy of precision medicine in selected patients
The presentations will discuss new approaches in the treatment of Alcohol Use Disorder (AUD), specifically developing a targeted approach through precision medicine.
- Precision medicine incorporates the genetic, environmental, and lifestyle factors of an individual to tailor a treatment that would be efficacious for that patient.
- “Presenting at this congress provides us with the opportunity to increase awareness of the significant need for additional treatments for patients with AUD.
- Emphasizing the development of innovative therapies rooted in precision medicine to address alcohol cravings and excessive consumption promotes the recognition of the necessity for diverse treatments for this condition,” said Dr. Johnson.
Retrieved on:
Wednesday, August 23, 2023
CHARLOTTESVILLE, Va., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it received notice from Nasdaq on August 21, 2023 that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).
Key Points:
- CHARLOTTESVILLE, Va., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it received notice from Nasdaq on August 21, 2023 that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).
- Nasdaq determined that for the last 10 consecutive business days, from August 7 through August 18, 2023, the closing bid price of the Company’s common stock has been at $1.00 per share or greater.
- Additionally, on August 22, 2023, the Company received notice from Nasdaq that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders' equity of at least $2,500,000.
- The Company has now successfully resolved both outstanding Nasdaq compliance issues and Nasdaq has advised that the matters are now closed.
University,
General Services Administration,
South Tyrol Option Agreement,
Option,
JMC Heavy Duty Vehicle,
NDA,
Business,
Sale,
Research and development,
Administration,
Development,
Data analysis,
Acquisition,
Patient,
Research,
FDA,
Pharmaceutical industry,
Cryptocurrency,
EU Charlottesville, Va., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the second quarter of 2023.
Key Points:
- Charlottesville, Va., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the second quarter of 2023.
- Moreover, the sale of our Purnovate business during the quarter provided non-dilutive funding and significantly reduced our current cash burn rate.
- Adial received an upfront payment of $450 thousand on the notification date (May 8, 2023).
- Net Income for the second quarter of 2023 included a gain of $2.66 million as a result of the Purnovate Sale.
The new CUSIP number for the Common Stock following the reverse split will be 00688A 205.
Key Points:
- The new CUSIP number for the Common Stock following the reverse split will be 00688A 205.
- On April 12, 2023, Adial held a Special Meeting of Stockholders in which the Company’s stockholders approved the reverse split.
- The Nasdaq Capital Market requires, among other things, that a listing company’s common stock maintain a minimum bid price of at least $1.00 per share.
- We believe this reverse split will not only allow us to regain compliance with Nasdaq’s minimum bid price requirement, but also tighten the public float in our stock, enabling us to attract a broader universe of investors.
Partnership,
Probability,
Adial, Virginia,
Heavy menstrual bleeding,
NDA,
ECG,
ICH,
Research,
QT,
AUD,
Patient,
Physician,
Risk,
MA,
FDA,
Safety,
Pharmaceutical industry,
Dietary supplement,
EU Reviewed the safety data from the ONWARD trial and did not express any concerns with the data.
Key Points:
- Reviewed the safety data from the ONWARD trial and did not express any concerns with the data.
- Confirmation of the importance of identifying a patient subgroup where a relevant treatment effect and compelling evidence of a favorable risk-benefit profile can be assessed.
- The new clinical development plan includes both the US and EU endpoints and will be designed to satisfy both US and EU AD04 submission requirements.
- Confirmation of the clinical development plan and pathway is currently being conducted by Adial’s clinical development and regulatory advisors.
CHARLOTTESVILLE, Va., June 01, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced today that it will be presenting at the Jefferies 2023 Global Healthcare Conference being held June 7-9, 2023, at the Marriott Marquis in New York, NY.
Key Points:
- CHARLOTTESVILLE, Va., June 01, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced today that it will be presenting at the Jefferies 2023 Global Healthcare Conference being held June 7-9, 2023, at the Marriott Marquis in New York, NY.
- Cary Claiborne, Chief Executive Officer of Adial Pharmaceuticals, is scheduled to present on Friday, June 9, 2023 at 12:15 p.m. Eastern Time.
- The presentation will be webcast live and available for replay at https://wsw.com/webcast/jeff281/adil/1821820 .
Exercise,
Federal Institute for Drugs and Medical Devices,
Medical device,
General Services Administration,
South Tyrol Option Agreement,
Federal Institute for Sustainable Development,
Health care,
Option,
Business,
Medication,
Research,
Sale,
Research and development,
Administration,
Development,
Acquisition,
United Kingdom,
FDA,
Regulation of tobacco by the U.S. Food and Drug Administration,
Economics,
Food,
MHRA,
Pharmaceutical industry,
Cryptocurrency CHARLOTTESVILLE, Va., May 12, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the first quarter of 2023.
Key Points:
- CHARLOTTESVILLE, Va., May 12, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the first quarter of 2023.
- The Option Agreement provides that the parties will enter into a final acquisition agreement for the sale of the Purnovate assets under previously agreed financial terms.
- Adial received an upfront payment of $450 thousand on the notification date (May 8, 2023).
- After a final acquisition agreement is signed Adial will receive approximately $0.9 million for Purnovate expenditures incurred and paid by Adial after December 1, 2022.
Adovate was recently formed by William Stilley, co-founder and former CEO of Adial, for the sole purpose of acquiring, funding and advancing Purnovate’s business.
Key Points:
- Adovate was recently formed by William Stilley, co-founder and former CEO of Adial, for the sole purpose of acquiring, funding and advancing Purnovate’s business.
- Any Purnovate expenses incurred on and subsequent to May 16, 2023, will become the responsibility of Adovate.
- Additionally, the Company will receive a single digit royalty and receive a 19.9% equity stake in Adovate.
- Moving forward my primary focus will be on Adovate and I am departing from my active management role with Adial.
Exercise,
Partnership,
Federal Institute for Drugs and Medical Devices,
Medical device,
General Services Administration,
Clinical trial,
Research,
Sale,
Research and development,
Administration,
Development,
AUD,
Acquisition,
Patient,
United Kingdom,
FDA,
Regulation of tobacco by the U.S. Food and Drug Administration,
Federal institutions of Tanzania,
Food,
Safety,
Pharmaceutical industry,
Life insurance,
Cryptocurrency CHARLOTTESVILLE, Va., March 30, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2022 fiscal year ended December 31, 2022.
Key Points:
- Advancing partnership activities in both the U.S. and Europe
CHARLOTTESVILLE, Va., March 30, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2022 fiscal year ended December 31, 2022.
- Cary Claiborne, President and Chief Executive Officer of Adial, stated, “We made significant advancements throughout 2022.
- ONWARD results showed that AD04 achieved a statistically significant reduction of heavy drinking days in the “heavy drinkers” subgroup of patients.
- Adial would receive $450,000 upon exercise of the option, and then be reimbursed for any Purnovate expenditures incurred and paid after December 1, 2022.
Kohlberg Kravis Roberts,
Trade,
Strategic planning,
National Association of Corporate Directors,
Business,
RBP,
Marketing,
Business administration,
Marshall University,
Corporation,
National Association,
FTSE,
FDA,
Management,
Indivior The Keswick Group is led by Tony Goodman, a current member of Adial’s board of directors.
Key Points:
- The Keswick Group is led by Tony Goodman, a current member of Adial’s board of directors.
- Mr. Goodman’s career spans over 23 years in the pharmaceutical and biotech industries.
- He is the founder and Managing Director of The Keswick Group, LLC.
- Mr. Goodman has also served as the Director of Strategic Marketing and Business Development at PRA International.
